237 related articles for article (PubMed ID: 21464312)
1. Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination.
Jo H; Lo PK; Li Y; Loison F; Green S; Wang J; Silberstein LE; Ye K; Chen H; Luo HR
Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6486-91. PubMed ID: 21464312
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic value of SC66 in human renal cell carcinoma cells.
Xu M; Wang Y; Zhou LN; Xu LJ; Jin ZC; Yang DR; Chen MB; Zhu J
Cell Death Dis; 2020 May; 11(5):353. PubMed ID: 32393791
[TBL] [Abstract][Full Text] [Related]
3. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.
Wu YH; Huang YF; Chen CC; Chou CY
Cell Death Dis; 2019 Apr; 10(4):322. PubMed ID: 30975980
[TBL] [Abstract][Full Text] [Related]
4. SC66 inhibits the proliferation and induces apoptosis of human bladder cancer cells by targeting the AKT/β-catenin pathway.
Chen W; Zhao S; Yu W; Rao T; Ruan Y; Zhu S; Xia Y; Song H; Cheng F
J Cell Mol Med; 2021 Nov; 25(22):10684-10697. PubMed ID: 34687144
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells.
Cusimano A; Puleio R; D'Alessandro N; Loria GR; McCubrey JA; Montalto G; Cervello M
Oncotarget; 2015 Jan; 6(3):1707-22. PubMed ID: 25596737
[TBL] [Abstract][Full Text] [Related]
6. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
Politz O; Siegel F; Bärfacker L; Bömer U; Hägebarth A; Scott WJ; Michels M; Ince S; Neuhaus R; Meyer K; Fernández-Montalván AE; Liu N; von Nussbaum F; Mumberg D; Ziegelbauer K
Int J Cancer; 2017 Jan; 140(2):449-459. PubMed ID: 27699769
[TBL] [Abstract][Full Text] [Related]
7. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation.
Kim D; Sun M; He L; Zhou QH; Chen J; Sun XM; Bepler G; Sebti SM; Cheng JQ
J Biol Chem; 2010 Mar; 285(11):8383-94. PubMed ID: 20068047
[TBL] [Abstract][Full Text] [Related]
8. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.
Parikh C; Janakiraman V; Wu WI; Foo CK; Kljavin NM; Chaudhuri S; Stawiski E; Lee B; Lin J; Li H; Lorenzo MN; Yuan W; Guillory J; Jackson M; Rondon J; Franke Y; Bowman KK; Sagolla M; Stinson J; Wu TD; Wu J; Stokoe D; Stern HM; Brandhuber BJ; Lin K; Skelton NJ; Seshagiri S
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19368-73. PubMed ID: 23134728
[TBL] [Abstract][Full Text] [Related]
9. Regulation of AKT Activity by Inhibition of the Pleckstrin Homology Domain-PtdIns(3,4,5)P
Kang Y; Jang G; Ahn S; Lee Y; Shim SY; Yoon Y
J Microbiol Biotechnol; 2018 Aug; 28(8):1401-1411. PubMed ID: 30301316
[TBL] [Abstract][Full Text] [Related]
10. PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis.
Yin S; Liu L; Brobbey C; Palanisamy V; Ball LE; Olsen SK; Ostrowski MC; Gan W
Nat Commun; 2021 Jun; 12(1):3444. PubMed ID: 34103528
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains.
Miao B; Skidan I; Yang J; Lugovskoy A; Reibarkh M; Long K; Brazell T; Durugkar KA; Maki J; Ramana CV; Schaffhausen B; Wagner G; Torchilin V; Yuan J; Degterev A
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20126-31. PubMed ID: 21041639
[TBL] [Abstract][Full Text] [Related]
12. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.
Estrada AC; Syrovets T; Pitterle K; Lunov O; Büchele B; Schimana-Pfeifer J; Schmidt T; Morad SA; Simmet T
Mol Pharmacol; 2010 Mar; 77(3):378-87. PubMed ID: 20018812
[TBL] [Abstract][Full Text] [Related]
13. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
Hampsch RA; Shee K; Bates D; Lewis LD; Désiré L; Leblond B; Demidenko E; Stefan K; Huang YH; Miller TW
Oncotarget; 2017 Mar; 8(13):21806-21817. PubMed ID: 28423521
[TBL] [Abstract][Full Text] [Related]
15. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.
Yu Y; Savage RE; Eathiraj S; Meade J; Wick MJ; Hall T; Abbadessa G; Schwartz B
PLoS One; 2015; 10(10):e0140479. PubMed ID: 26469692
[TBL] [Abstract][Full Text] [Related]
16. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
Lindsley CW; Barnett SF; Yaroschak M; Bilodeau MT; Layton ME
Curr Top Med Chem; 2007; 7(14):1349-63. PubMed ID: 17692025
[TBL] [Abstract][Full Text] [Related]
18. Mcl-1 Interacts with Akt to Promote Lung Cancer Progression.
Chen G; Park D; Magis AT; Behera M; Ramalingam SS; Owonikoko TK; Sica GL; Ye K; Zhang C; Chen Z; Curran WJ; Deng X
Cancer Res; 2019 Dec; 79(24):6126-6138. PubMed ID: 31662324
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.
Moses SA; Ali MA; Zuohe S; Du-Cuny L; Zhou LL; Lemos R; Ihle N; Skillman AG; Zhang S; Mash EA; Powis G; Meuillet EJ
Cancer Res; 2009 Jun; 69(12):5073-81. PubMed ID: 19491272
[TBL] [Abstract][Full Text] [Related]
20. Pleckstrin homology domain of Akt kinase: a proof of principle for highly specific and effective non-enzymatic anti-cancer target.
Joh EH; Hollenbaugh JA; Kim B; Kim DH
PLoS One; 2012; 7(11):e50424. PubMed ID: 23189201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
